We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
The effect of desvenlafaxine 50 mg/day on a subpopulation of anxious/depressed patients: a pooled analysis of seven randomized, placebo-controlled studies.
- Authors
Kornstein, Susan G.; Guico‐Pabia, Christine J.; Fayyad, Rana S.
- Abstract
Background Desvenlafaxine (administered as desvenlafaxine succinate) for anxious depression was assessed in a post hoc analysis. Methods Data were pooled from patients randomly assigned to desvenlafaxine 50 mg/day or placebo in seven double-blind, fixed-dose studies in adults with major depressive disorder. Patients with 'anxious depression' had baseline 17-item Hamilton Rating Scale for Depression, anxiety-somatization factor (HAM-D17 A/S) scores ≥7. Primary end point was change in HAM-D17 scores from baseline at week 8 (last observation carried forward), evaluated using analysis of covariance with treatment, study, and baseline value as covariates. Results A total of 1873/2706 (69%) patients were identified as 'anxious depressed'. Desvenlafaxine significantly improved HAM-D17 total scores versus placebo in anxious (adjusted mean [95% CI] −1.72 [−2.35, −1.09]; p < 0.001) and nonanxious (−1.48 [−2.40, −0.57]; p = 0.002) populations, with no significant treatment-by-anxiety interaction. Response and remission rates (HAM-D17) were significantly higher with desvenlafaxine compared with placebo in both populations. Treatment-emergent adverse events were reported by 78% and 69% (desvenlafaxine versus placebo, respectively) of anxious depressed patients and by 77% and 68% of nonanxious patients. Conclusion Desvenlafaxine 50 mg/day significantly improved depressive symptoms compared with placebo in major depressive disorder patients with clinically relevant anxiety symptoms. Improvement in the HAM-D17 total score was similar for anxious/nonanxious groups. Copyright © 2014 John Wiley & Sons, Ltd.
- Subjects
DEPRESSED persons; MENTAL depression; ANXIETY treatment; DRUG efficacy; PATHOLOGICAL psychology; SOCIETIES
- Publication
Human Psychopharmacology: Clinical & Experimental, 2014, Vol 29, Issue 5, p492
- ISSN
0885-6222
- Publication type
Article
- DOI
10.1002/hup.2427